Abstract: A light polymerizable composition for use in the additive manufacturing of medical devices may include a first photo-initiator and a second photo-initiator. The first photo-initiator activates to initiate curing of the composition when exposed to light of a first wavelength in an additive manufacturing device and the second photo-initiator limits the transmission of the light of the first wavelength that activates the first photo-initiator in the additive manufacturing device. The second photo-initiator is activated to further cure the composition when exposed to a light of a second wavelength different from the first wavelength by activating the second photo-initiator to produce free radicals at a higher rate when exposed to the light of the second wavelength than when exposed to the light of the first wavelength.

Abstract: A composition, a gas diffusion electrode, and a method for fabricating the same is disclosed. In an example, the composition includes carbon supported carboxyl surface functionalized silver nanoparticles. The gas diffusion electrode can be fabricated with the carbon supported carboxyl surface functionalized silver nanoparticles and deployed in a membrane electrode assembly for various applications.

Abstract: A system includes a plurality of drug libraries, at least one comprising multiple droplets of multiple drugs, each drug associated with a corresponding unique drug identifier in the system, and a live cell library comprising multiple live cells or live cell lines, each live cell associated with a corresponding unique cell or cell line identifier in the system. A plurality of junctions combining drug droplets from the drug libraries and a live cell from the live cell library. At least one of said drug libraries produces a random stream of heterogenous drug droplets, the drug droplets corresponding to drugs in said drug libraries.

Abstract: Disclosed herein are devices, systems, methods and platforms for continuously monitoring the health status of a user, for example the cardiac health status. The present disclosure describes systems, methods, devices, software, and platforms for continuously monitoring a user's low-fidelity health-indicator data (for example and without limitation PPG signals, heart rate or blood pressure) from a user-device in combination with corresponding (in time) data related to factors that may impact the health-indicator (“other-factors”) to determine whether a user has normal health as judged by or compared to, for example and not by way of limitation, either (i) a group of individuals impacted by similar other-factors, or (ii) the user him/herself impacted by similar other-factors.

Abstract: Systems and methods for gesture control are described. In some embodiments, a system may include a wearable device configured to be worn on a wrist of a user. The wearable device ma include a hub and a wristband. The hub may include a plurality of hub electrodes and a biopotential microchip. The wristband may include one or more wristband electrodes and one or more wristband conductors, which may electrically connecting the one or more wristband electrodes to the electrical port of a sealed housing of the hub, which may in turn electrically connect the one or more wristband electrodes to inputs of the biopotential microchip.

Abstract: Various embodiments are disclosed for providing machine learning routines with peripheral device data to infer driver activity and location. Peripheral device data may be collected on a peripheral device having a machine learning routine executing thereon to infer driver activity and perform improved estimation of driver location. Using driver activity and location estimation, contextually relevant delivery workflow assistance may be automatically provided to a delivery driver or other individual without requiring manual input, thereby improving driver safety and operational efficiency.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Abstract: A method of forming a tungsten-containing layer over a substrate includes a) positioning a substrate on a substrate support in a process volume of a process chamber; b) providing a precursor gas to the process volume of the process chamber for a first duration; and c) providing a tungsten-containing gas to the process volume of the process chamber by opening a pulsing valve on a tungsten-containing gas delivery line for a second duration occurring after the first duration to form a tungsten-containing layer on the substrate. The tungsten-containing gas delivery line includes a first section connected to an inlet of the pulsing valve and a second section connected to an outlet of the pulsing valve, the first section connects the inlet of the pulsing valve to a reservoir of tungsten-containing gas, the second section connects the outlet of the pulsing valve to an inlet of the process chamber.

Abstract: A method of generating customizable goal representation is disclosed. A request from a user to view a goal representation is received. A flexible goal ontology is accessed that comprises one or more goal entities, one or more goal relationships between the goal entities, or one or more goal properties, the one or more goal properties including one or more metadata attributes relating to the one or more goal entities. A set of mapping rules is obtained that defines mappings between one or more goals. The set of mapping rules is evaluated to assemble a customized goal representation tailored to the user. The customized goal representation is updated based on a revaluation of the mapping rules affected by changes to the one or more goal entities, the one or more goal relationships, or the one or more properties.

Abstract: A wearable computing device includes a housing having a wrist-side face configured to sit against a wrist of a user of the wearable computing device when being worn by the user, an electronic display arranged within the housing, a plurality of biometric sensor electrodes positioned on the wrist-side face so as to maintain skin contact with the user when being worn on the wrist by the user, and at least one driver communicatively coupled to the plurality of biometric sensor electrodes. Each of the plurality of biometric sensor electrodes continuously measures, at least, one or more parameters indicative of electrical impedance of the user at a location of the skin contact.

Abstract: Features relating to a vaporizer body are provided. The vaporizer body may include an outer shell that includes an inner region defined by an outer shell sidewall. A support structure is configured to fit within the inner region of the outer shell. The support structure includes a storage region defined by a top support structure, a bottom support structure, a bottom cap, and a gasket. An integrated board assembly is configured to fit within the storage region of the support structure. The integrated board assembly may include a printed circuit board assembly formed of multiple layers that form a rigid structure and that include an inner, flexible layer. A first antenna is integrated at a proximal end of the flexible layer, and a second antenna is integrated at a distal end of the flexible layer.

Abstract: Aspects herein provide a system, media, and methods for a mobile edge computer that renders extended reality (XR) in support of a local user device, via a local network. The mobile edge computer can continue to provide updated XR renderings in near real-time when user position data remains within a particular viewing angle, without requesting updated content or rendering assistance from a remote application. When user position data is determined to be outside of the viewing angle, then the mobile edge computer may request additional content from the remote application.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

Abstract: A surface cleaning apparatus including a body defining an agitation chamber, an agitator partially disposed within the agitation chamber and configured to rotate about a pivot axis, and a debrider at least partially disposed within the agitation chamber. The agitator includes an elongated body having a first and a second end, a sidewall extending radially outward from the elongated body extending between the first and the second ends, and a plurality of bristles extending radially outward from the elongated body. The plurality of bristles are arranged in at least one row adjacent to the sidewall. The debrider includes a plurality of teeth configured to contact a portion of the sidewall as the agitator rotates about the pivot axis.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for detecting errors in a client device and its associated applications while preserving the privacy of the user of the device. Methods can include obtaining and blinding contextual application data for an application on a device. Data regarding the application's digital certificate and device trustworthiness data are obtained and provided to a trust assessment server along with the blinded data. This server can provide indications that the device is trustworthy and the application is authentic, and can digitally sign the blinded data. The digital signature can be validated and the unblinded contextual application data can be obtained. If the unblinded data matches the contextual application data, the application can provide the digital signature, the indications, and the unblinded contextual application data to an error detection server, which in turn can indicate the application does not have errors.

Abstract: In various examples, a yield scenario may be identified for a first vehicle. A wait element is received that encodes a first path for the first vehicle to traverse a yield area and a second path for a second vehicle to traverse the yield area. The first path is employed to determine a first trajectory in the yield area for the first vehicle based at least on a first location of the first vehicle at a time and the second path is employed to determine a second trajectory in the yield area for the second vehicle based at least on a second location of the second vehicle at the time. To operate the first vehicle in accordance with a wait state, it may be determined whether there is a conflict between the first trajectory and the second trajectory, where the wait state defines a yielding behavior for the first vehicle.

Abstract: Fibrous structures containing filaments and solid additives, and more particularly to fibrous structures containing filaments and solid additives wherein the fibrous structure has three or more regions that exhibit different characteristics and/or properties and methods for making same, are provided.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Abstract: The present invention relates to a hexatoxin peptide variant comprising a. an amino acid sequence which is at least 90% identical to any one of SEQ ID NOs: 27 to 29, wherein the amino acid sequence has at least one amino acid variant on position N27; b. an amino acid sequence which is at least 90% identical to any one of SEQ ID NOs: 2, 6, 7, 30 or 32, wherein the amino acid sequence has at least one amino acid variant on position N28; c. an amino acid sequence which is at least 90% identical to any one of SEQ ID NOs: 1, 3, 4, 5, 8 to 24 or 31, wherein the amino acid sequence has at least one amino acid variant on position N29; d. an amino acid sequence which is at least 90% identical to SEQ ID NO: 25, wherein the amino acid sequence has at least one amino acid variant on position N30; e. an amino acid sequence which is at least 90% identical to SEQ ID NOs: 26, wherein the amino acid sequence has at least one amino acid variant on position N31; or f.